KR20100040165A - Stock feed composition containing blend of 5-aminolevulinic acid and fermented kitosan as active ingredient - Google Patents
Stock feed composition containing blend of 5-aminolevulinic acid and fermented kitosan as active ingredient Download PDFInfo
- Publication number
- KR20100040165A KR20100040165A KR1020080099261A KR20080099261A KR20100040165A KR 20100040165 A KR20100040165 A KR 20100040165A KR 1020080099261 A KR1020080099261 A KR 1020080099261A KR 20080099261 A KR20080099261 A KR 20080099261A KR 20100040165 A KR20100040165 A KR 20100040165A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- feed
- feed composition
- ala
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
- A23K10/22—Animal feeding-stuffs from material of animal origin from fish
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Birds (AREA)
- Fodder In General (AREA)
Abstract
Description
본 발명은 면역력 증진 및 항생제 대체용 가축사료 조성물에 관한 것으로, 더욱 상세하게는 5-아미노레불린산(ALA)과 키토산 발효물의 합제를 유효성분으로 함유하는 가축사료를 제공함으로써 동물의 항생제 대체, 면역증가효과 및 성장 촉진 효과가 있는 사료를 제공할 수 있는 내용에 관한 것이다.The present invention relates to an animal feed composition for enhancing immunity and replacing antibiotics, and more particularly, to provide an animal feed containing a combination of 5-aminolevulinic acid (ALA) and a chitosan fermentation as an active ingredient, thereby replacing animal antibiotics. It relates to the contents that can provide a feed having an immune boosting effect and a growth promoting effect.
경제발전과 더불어 동물생산업도 좁은 공간에서의 대량사육형태로 바뀌면서 동물의 스트레스 발생 및 면역결핍현상으로 인해 다양한 질병이 발생하게 되었다. 이를 사전에 예방하거나 치료하기 위해 항생제를 남용하게 되고, 그로 인한 항생제 내성문제 발생, 축산물에의 항생제 잔류 등의 여러 가지 부작용이 야기됨으로써 국민 보건을 위협하는 수준에 이르렀다.Along with economic development, the animal life industry has also changed to mass breeding in a narrow space, resulting in various diseases due to stress and immunodeficiency of animals. Antibiotics are abused to prevent or cure them in advance, resulting in a number of side effects such as antibiotic resistance problems and the retention of antibiotics in livestock products.
유럽연합(EU)은 성장촉진목적으로 동물용 사료에 항생제를 첨가하는 것을 이미 금지하였고 질병치료목적으로의 항생제 사용도 엄격한 절차를 밟도록 하는 추세이며, 우리나라 정부에서도 이와 같은 방향으로 정책을 추진하고 있으므로 동물산 업의 생존 및 국민건강을 위해서 항생제를 대체할 수 있는 제제의 개발이 절실한 상황이다.The EU has already banned the addition of antibiotics to animal feed for the purpose of promoting growth, and the use of antibiotics for the treatment of diseases has also been a strict procedure. The development of drugs that can replace antibiotics for the survival of the animal industry and national health is urgently needed.
현재까지 동물의 면역력 향상 및 항생제 대체효과를 가진 소재들이 다양하게 개발되고 있으나, 효능이 확실치 않거나 생산효율이 낮아 동물에 적용하기에는 한계점이 많은 실정이다.To date, a variety of materials have been developed to improve the immunity of animals and to replace antibiotics, but there are many limitations to apply to animals due to uncertainty or low production efficiency.
5-아미노레불린산(5-aminolevulinic acid, ALA)은 생체내 헴(heme) 합성의 전구물질로서, 그동안 암치료제, 제초제, 식물성장조절제, P450 생산용 전구체 등 다양한 분야에서의 적용에 대한 연구가 많이 이루어지고 있으며, 최근 들어 동물의 항생제 대체 및 면역증강효과를 가지고 있다. 그러나 이러한 5-아미노레불린산(ALA)과 키토산 발효물을 함께 첨가한 사료를 가축에 급여한 경우 본 발명에서와 같은 현저한 효과를 입증한 내용에 관하여 아직 밝혀진 바 없다. 5-aminolevulinic acid (ALA) is a precursor of heme synthesis in vivo, and has been studied in various fields such as cancer therapy, herbicides, plant growth regulators, and precursors for P450 production. It has been made a lot, and recently has the antibiotic replacement and immune boosting effect of the animal. However, it is not yet clear about the contents which proved a remarkable effect as in the present invention when feeding a feed supplemented with 5-aminolevulinic acid (ALA) and chitosan fermented products to livestock.
본 발명은 상기와 같은 요구에 의해 안출된 것으로서, 본 발명은 축산업 분야에서 사용되는 통상의 제조 사료에 ALA-키토산 발효물 합제를 배합함으로써, 다량의 항생제를 배합하였을 때와 같은 우수한 성장률과 면역력을 갖는 가축을 생산하면서도, 가축과 그 육제품을 섭취한 인체에 해를 끼치는 항생제의 사용을 전부/일부를 배제시켜 안전한 육제품의 생산을 위한 가축사료 조성물을 제공하고자 한다. The present invention has been made by the above-mentioned demands, and the present invention provides the same growth rate and immunity as when a large amount of antibiotics is formulated by combining ALA-chitosan fermented product mixture with a conventionally prepared feed used in the livestock industry. It is intended to provide a livestock feed composition for the production of safe meat products while producing all livestock, while eliminating all / some of the use of antibiotics that harm the human body ingesting livestock and their meat products.
상기 과제를 해결하기 위해, 본 발명은 5-아미노레불린산(ALA)과 키토산 발효물의 합제를 유효성분으로 함유하는 면역력 증진 및 항생제 대체용 가축사료 조성물을 제공한다.In order to solve the above problems, the present invention provides a livestock feed composition for immunity enhancement and antibiotic replacement containing a combination of 5-aminolevulinic acid (ALA) and chitosan fermentation as an active ingredient.
본 발명은 또한, 상기 가축사료 조성물을 포함하는 가축사료를 제공한다.The present invention also provides a livestock feed comprising the livestock feed composition.
본 발명은 가축 면역력 향상을 위한 물질 및 항생제 대체 물질인 ALA-키토산 발효물 합제를 개발함으로써 안전한 축산물 생산을 가능하게 하는 가축사료 조성물을 제공할 수 있다.The present invention can provide a livestock feed composition that enables the production of safe livestock by developing a mixture of ALA-chitosan fermented product which is an antibiotic substitute and a substance for improving animal immunity.
본 발명에 따른 가축사료는, ALA-키토산 발효물 합제를 가축의 성장상태에 따라 해당 가축사료에 일정비율로 배합시킴으로써, 가축사료에 배합되는 항생제의 전부를 배제시킬 수 있도록 한 것이다. Livestock feed according to the present invention is to mix the ALA-chitosan fermented product mixture in a predetermined proportion to the animal feed according to the growth state of the livestock, it is possible to exclude all of the antibiotics blended into the livestock feed.
본 발명에서 적용된 상기 ALA-키토산 발효물 합제는 5-아미노레불린산(ALA)과 키토산 발효물의 합제이다. 5-아미노레불린산(ALA)은 생체내 헴(heme) 합성의 전구물질로서, 그동안 암치료제, 제초제, 식물성장조절제, P450 생산용 전구체 등의 기능을 가지고 있으며, 키토산 발효물은 키토산 및 키토산 올리고당을 Bacillus MJ-1 균주(KCTC 18116P, 대한민국 특허출원번호 2006-0076392)로 발효시켜 가축의 면역력을 증진시켜 가축 생산성을 향상시킨다.The ALA-chitosan fermentation mixture applied in the present invention is a combination of 5-aminolevulinic acid (ALA) and chitosan fermentation. 5-aminolevulinic acid (ALA) is a precursor of heme synthesis in vivo, and has been used as a cancer treatment agent, herbicide, plant growth regulator, precursor for P450 production, and chitosan fermentation products are chitosan and chitosan. Oligosaccharides are fermented with Bacillus MJ-1 strain (KCTC 18116P, Korean Patent Application No. 2006-0076392) to enhance the immunity of the livestock and improve the livestock productivity.
또한, 사육되는 가축들은 많은 질병에 걸릴 위험이 있으며, 이를 예방하기 위해 백신을 투여하는 경우가 많은데, 이러한 백신으로 인해 성장의 저하를 초래하 게 되므로 축산가들에게 경제적인 손실을 가져온다. 반면에, 본 발명에서와 같이 ALA-키토산 발효물 합제를 첨가하면 면역성을 높이는 효과를 가져오기 때문에 질병에 걸릴 빈도수가 감소되어 가축의 생산성을 향상시킬 수 있게 된다. 즉, ALA-키토산 발효물 합제 자체는 가축의 면역력을 높여 인위적인 항생제 및 소염제 등의 사용을 소량으로 제한하여도 가축의 질병을 예방할 수 있을 뿐만 아니라, 그 가축을 섭취한 인체에도 유해물질의 농축현상을 유발하지 않게 되며, 이에 따라 우량한 가축의 생산과 고품질의 돈육을 생산하는데 크게 기여를 할 수 있을 것이다. In addition, domesticated cattle are at risk of many diseases, and vaccines are often administered to prevent them, which can cause economic losses for livestock farmers because of the slow growth of these vaccines. On the other hand, since the addition of the ALA-chitosan fermented product mixture as in the present invention has an effect of increasing the immunity can reduce the frequency of disease can improve the productivity of the livestock. In other words, the ALA-chitosan fermentation mixture itself can increase the immunity of livestock and prevent the disease of livestock even if it restricts the use of artificial antibiotics and anti-inflammatory agents in small amounts. This will not contribute to the production of high quality livestock and thus will contribute greatly to the production of superior livestock and high quality pork.
이하 본 발명의 내용을 더욱 상세하게 설명하기로 한다.Hereinafter, the content of the present invention will be described in more detail.
본 발명은 5-아미노레불린산(ALA)과 키토산 발효물의 합제를 유효성분으로 함유하는 면역력 증진 및 항생제 대체용 가축사료 조성물을 제공한다. The present invention provides a feed composition for improving immunity and antibiotic replacement containing a combination of 5-aminolevulinic acid (ALA) and chitosan fermentation as an active ingredient.
본 발명의 일구현예에 따른 상기 합제는 기초사료에 0.1~0.2%로 첨가하는 것이나, 바람직하게는 0.2%로 첨가하는 것이다. The mixture according to one embodiment of the present invention is to be added to the basic feed in 0.1 to 0.2%, preferably to 0.2%.
본 발명의 일구현예에 따른 상기 기초사료는 주성분이 옥수수, 대두박, 유청, 어분, 당밀, 소금, 비타민 프리믹스 및 미네랄 프리믹스로 이루어진 것을 특징으로 한다. 비타민 프리믹스는 비타민 A, 비타민 D, 비타민 E, 리보프라빈 및 나이아신으로 구성될 수 있으며, 미네랄 프리믹스는 망간, 철 아연, 칼슘, 구리, 코발트 및 셀레니늄 등으로 구성될 수 있다.The basic feed according to an embodiment of the present invention is characterized in that the main ingredient consists of corn, soybean meal, whey, fish meal, molasses, salt, vitamin premix and mineral premix. Vitamin premixes may consist of vitamin A, vitamin D, vitamin E, riboprabin and niacin, and mineral premixes may consist of manganese, iron zinc, calcium, copper, cobalt and selenium.
본 발명의 일구현예에 따른 상기 기초사료는 기초사료 100중량부에 대하여 옥수수 45.23중량부, 대두박 26.07중량부, 유청 16중량부, 어분 5.00중량부, 우지 3.00중량부, 석회석 0.52중량부, 인산칼슘 1.16중량부, 당밀 2.5중량부, 소금 0.25중량부, 비타민 프리믹스 0.12중량부, 미네랄 프리믹스 0.10중량부 및 산화방지제 0.05중량부의 조성으로 이루어진 이유자돈 사료인 것을 특징으로 한다. 상기 산화방지제로는 Ethoxyquin을 사용할 수 있으나, 이에 제한되지 않는다.The basic feed according to an embodiment of the present invention is 45.23 parts by weight of corn, 26.07 parts by weight of soybean meal, 16 parts by weight of whey, 5.00 parts by weight of fishmeal, 3.00 parts by weight, 0.52 parts by weight of limestone, phosphoric acid based on 100 parts by weight of basic feed It is characterized in that the weaning pig feed consisting of the composition of 1.16 parts by weight of calcium, 2.5 parts by weight of molasses, 0.25 parts by weight of salt, 0.12 parts by weight of vitamin premix, 0.10 parts by weight of mineral premix and 0.05 parts by weight of antioxidant. Ethoxyquin may be used as the antioxidant, but is not limited thereto.
본 발명은 또한 상기 가축사료 조성물을 포함하는 가축사료를 제공한다.The present invention also provides a livestock feed comprising the livestock feed composition.
이하 본 발명의 내용을 실시예를 통해 더욱 상세하게 설명하기로 한다. 다만, 이들 실시예는 본 발명의 내용을 이해하기 위해 제시되는 것일 뿐 본 발명의 권리범위가 이들 실시예로 한정되는 것은 아니다.Hereinafter, the contents of the present invention will be described in more detail with reference to Examples. However, these examples are only presented to understand the content of the present invention, but the scope of the present invention is not limited to these embodiments.
<실시예 1. ALA 단독으로 사료에 첨가하여 가축에 급여한 경우><Example 1. ALA added to feed alone to feed livestock>
ALA의 경우 아래 표 1과 같이 소화율에 긍정적인 영향을 미치며, 염증반응 유도시 항염증작용의 가능성을 외국 논문을 통해 발표한바 있다(Livestock science, 114(2008) 108-116).In the case of ALA, it has a positive effect on digestibility as shown in Table 1 below, and the possibility of anti-inflammatory action in inducing an inflammatory response has been published in a foreign paper (Livestock science, 114 (2008) 108-116).
이유자돈 사료내 ALA 첨가시 시험 후 35일째에 ALA 첨가수준이 증가함에 따라 DM(건물)과 N(질소, 단백질) 소화율에서 유의적으로 증가함을 보였다(p<0.01).The addition of ALA in weaned pigs was significantly increased in DM (building) and N (nitrogen, protein) digestibility at 35 days after the test (p <0.01).
이유자돈 사료내 ALA 첨가 유무에 따른 LPS(급성염증반응 발현물질) 공격 접종시 혈액내 Cortisol(스트레스호르몬) 농도에서 접종 2시간째 감소시켜주는 효과를 보였으며(p<0.01), 12시간째에도 이러한 경향을 보였다(p=0.07). IGF-I(성장촉진호르몬) 농도에서도 2시간째에 ALA 첨가구의 경우 높았다(p<0.05). 또한 TNF-α(종양괴사인자)에서도 ALA 첨가구가 2시간째에 유의적으로 낮았으며(p<0.05), 4시간째에도 낮은 경향을 보였다(p=0.09)(표2). 이로써 ALA는 이유자돈의 면역작용을 상승시키는 것을 알 수 있게 한다.Induction of LPS (Acute Inflammatory Response) with or without ALA in weaned pigs was shown to reduce the blood Cortisol (stress hormone) concentration at 2 hours of inoculation (p <0.01), and at 12 hours Tendency was shown (p = 0.07). The IGF-I concentration was higher in the ALA-added group at 2 hours (p <0.05). In addition, TNF-α (tumor necrosis factor) was significantly lower at 2 hours after addition of ALA (p <0.05) and at 4 hours (p = 0.09) (Table 2). This makes it possible to see that ALA raises the immune function of weaning piglets.
<실시예 2. 키토산 발효물 단독으로 사료에 첨가하여 가축에 급여한 경우><Example 2. Chitosan fermented product added to feed alone when fed to livestock>
또한 키토산 발효물의 경우 아래와 같이 성장, 소화율에 긍정적으로 작용한다는 보고가 있다(진 등,2008; 3월 미국 축산학회 발표자료).In addition, chitosan fermented products have been reported to have a positive effect on growth and digestion rate as described below (Jin et al., 2008;
표 3에 나타낸 바와 같이 이유자돈 사료내 키토산 발효물 첨가가 성장에 미치는 영향을 보면 시험 후 15-28일까지 및 시험 전 기간(0-28일) 키토산 발효물 첨가수준이 증가함에 따라 ADG(일당증체량)와 ADFI(일당사료섭취량)가 증가하는 경향을 보였다(p<0.10).As shown in Table 3, the effect of the addition of chitosan fermentation in the weaning pig feed on growth was increased by 15-28 days after the test and as the level of chitosan fermentation increased before the test (0-28 days). ) And ADFI (daily feed intake) tended to increase (p <0.10).
표 4에 나타낸 바와 같이 이유자돈 사료내 키토산 발효물 첨가가 영양소 소화율에 미치는 영향을 보면 시험 종료시(28일) DM(건물)과 N(질소, 단백질) 소화율에서 5g/kg의 키토산 발효물 첨가시 무첨가보다 유의적으로 높은 소화율을 보였다(p<0.05). 또한 건물 소화율에서 키토산 발효물의 첨가수준이 증가함에 따라 소화율이 증가하였으며(p<0.05), 질소 소화율에서도 키토산 발효물의 첨가수준이 증가함에 따라 소화율이 증가하는 경향을 보였다(p<0.10).As shown in Table 4, the effect of the addition of chitosan fermented product to weaning pig feed on nutrient digestibility was not added when 5 g / kg of chitosan fermented product was added at the end of the test (28 days) in DM (building) and N (nitrogen, protein) digestibility. The digestibility was significantly higher (p <0.05). In addition, the digestibility increased with increasing chitosan fermentation level in dry matter digestibility (p <0.05), and the digestibility increased with increasing level of chitosan fermentation in nitrogen digestion rate (p <0.10).
<실시예 3. ALA-키토산 발효물 합제의 효능 측정 방법><Example 3. Efficacy measuring method of ALA-chitosan fermented product mixture>
3원 교잡종(Duroc×Yorkshire×Landrace) 이유자돈 120두를 공시하였으며, 시험개시시의 체중은 7.10kg 이었다. 사양시험은 단국대학교 실험 연구동에서 실시하였다. 시험설계는 표 5와 같이 옥수수, 대두박 위주의 기초사료(무항생제 구)에, 아빌라마이신 40ppm과 옥시테트라사이클린 100ppm를 첨가한 항생제 구, 무항생제 사료에 ALA-키토산 발효물 합제를 0.1% 첨가한 구, 무항생제 사료에 ALA-키토산 발효물 합제를 0.2% 첨가한 구의 4개구로 처리하여 처리당 6반복, 반복당 5두씩 완전 임의 배치하였다. 120 heads of three-way hybrids (Duroc × Yorkshire × Landrace) were disclosed. The weight of the test was 7.10 kg. The specification test was conducted in the experimental research building of Dankook University. As shown in Table 5, 0.1% of ALA-chitosan fermented product mixture was added to corn and soybean meal-based basic feeds (antibiotic spheres), antibiotics containing 40 ppm of avilamycin and 100 ppm of oxytetracycline, and non-antibiotic feed. The treatments were treated with four mouths containing 0.2% ALA-chitosan fermented product mixture in the mouth and the antibiotic-free diets, and the cells were randomly placed in six repeats and five heads per treatment.
일반적인 사료의 옥수수와 소맥은 에너지 공급원이고 콩에서 기름을 뺀 대두박, 치즈가공 후 남은 부산물인 유청 및 어류를 건조시킨 후 분쇄한 어분은 단백질 공급원이다. 우지는 가축의 지방에서 추출한 기름으로 에너지를 보충해주는 원료이며 인산칼슘제와 석회석은 뼈를 구성하는 칼슘과 인을 공급하는 원료이다. 비타민 프리믹스는 비타민 A, 비타민 D, 비타민 E, 리보프라빈 및 나이아신으로 구성될 수 있으며, 미네랄 프리믹스는 망간, 철 아연, 칼슘, 구리, 코발트 및 셀레니늄 등으로 구성될 수 있다.Corn and wheat are common sources of energy, and soybean meal without soybeans, whey and by-products left after cheese processing are dried and ground fish meal is a protein source. Uji is a source of energy supplemented with oil extracted from livestock fats. Calcium phosphate and limestone are the sources of calcium and phosphorus that make up bone. Vitamin premixes may consist of vitamin A, vitamin D, vitamin E, riboprabin and niacin, and mineral premixes may consist of manganese, iron zinc, calcium, copper, cobalt and selenium.
또한, 상기 기초사료에는 NRC(1998) 사양표준을 기초로 하여 3,500㎉ 대사에너지/kg, 21.52% 조단백질, 1.33% 라이신(lysine), 0.75% 칼슘(Ca), 0.64% 인(P)을 함유토록 하였다. 시험사료는 가루사료의 형태로 자유 채식토록 하였으며, 물은 자동급수기를 이용하여 자유로이 먹을 수 있도록 하였다.In addition, the basic feed contains 3,500 kV metabolic energy / kg, 21.52% crude protein, 1.33% lysine, 0.75% calcium (Ca), and 0.64% phosphorus (P) based on the NRC (1998) specification. It was. The test feed was made free of vegetarian food in the form of powder feed, and the water was freely eaten by using an automatic water dispenser.
표 5. 사료배합비Table 5. Feed Mixing Ratio
시험사료를 42일간 급여후 각 처리구별 일당증체량(ADG), 일당사료섭취량(ADFI), 사료효율(G/F), 일반성분 소화율 및 혈액내 면역지표를 측정하였으며, 측정방법은 아래와 같으며, 당업계의 통상적인 방법으로 수행하였다.After 42 days of feeding the test feed, the daily weight gain (ADG), daily feed intake (ADFI), feed efficiency (G / F), general ingredient digestibility, and blood immunoassay were measured. It was carried out by conventional methods in the art.
시험개시시, 1주차, 3주차, 6주차(종료시)에 걸쳐 체중 및 사료섭취량을 측정하여 체중의 차이와 사료섭취량을 기준으로 일당증체량, 일당사료섭취량, 사료효율을 계산하였으며, 시험 1주, 3주, 6주(종료)에 걸쳐 건물 및 질소 소화율을 측정하였다. 소화율 측정 7일 전부터 사료내 불소화성 물질인 Cr2O3를 0.2% 첨가 급여후 분을 채취하여 건물 및 질소 소화율을 측정하였다. 시험개시시와 종료시에 경정 맥(Jugular vein)에서 혈청과 혈장을 채취하여 적혈구(RBC), 백혈구(WBC), 림프구(Lymphocyte), 헤모글로빈(Hb), 철분(Iron), 철결합능력(TIBC)을 분석하였다.The body weight and feed intake were measured at the beginning of the test, week 1, 3, and 6 (end) to calculate the daily gain, feed intake, and feed efficiency based on the difference in body weight and feed intake. Dry matter and nitrogen digestibility were measured over three and six weeks (end). Digestibility was measured 7 days before digestion was measured by adding 0.2% of Cr 2 O 3 feed fluorinated substances in the feed and dry matter and nitrogen digestibility was measured. Serum and plasma were collected from the jugular vein at the beginning and end of the test, and red blood cells (RBC), white blood cells (WBC), lymphocytes (Lymphocyte), hemoglobin (Hb), iron (Iron), iron binding capacity (TIBC) Was analyzed.
<실시예 4. ALA-키토산 발효물 합제가 성장능력에 미치는 영향>Example 4 Influence of ALA-chitosan Fermentation Mixture on Growth Capacity
이유자돈 사료 내 ALA-키토산 발효물 합제의 첨가가 성장능력에 미치는 영향은 표 6에 나타내었다. 0-7일 동안 일당증체량은 ANT 처리구가 대조구에 비교하여 유의적으로 증가하였다(p<0.05). 8-21일 동안 일당증체량은 ANT, AF2 처리구가 대조구와 비교하여 유의적으로 증가하였고(p<0.05), 일당사료섭취량에서는 대조구가 다른 처리구들보다 유의적으로 낮았다(p<0.05). 22-42일 동안 일당증체량은 ANT, AF2 처리구가 가장 높았으며(p<0.05), AF1 처리구가 대조구보다 유의적으로 높았다(p<0.05). 또한 사료효율에 있어서도 ANT 처리구가 대조구보다 유의적으로 높았다(p<0.05). 총 사양기간(0-42일)동안 일당증체량에 있어서 ANT, AF2 처리구가 대조구보다 유의적으로 높았으며(p<0.05), 사료효율에 있어서도 ANT 처리구가 대조구보다 높았다(p<0.05).The effect of the addition of ALA-chitosan fermented product mixture on weaning pig feed is shown in Table 6. The daily gain for 0-7 days was significantly increased in the ANT treatment compared to the control (p <0.05). For 8-21 days, the daily gain increased significantly in the ANT and AF2 treatments compared to the control (p <0.05), and the control in the daily intake was significantly lower than the other treatments (p <0.05). The daily gain was 22-42 days in ANT and AF2 treatments (p <0.05), and AF1 treatments were significantly higher than control (p <0.05). In addition, ANT treatment was significantly higher in the feed efficiency than the control (p <0.05). The ANT and AF2 treatments were significantly higher than the control group (p <0.05) and the ANT treatments were higher than the control group (p <0.05).
기존 키토산 발효물 처리시 시험 전체 기간동안 2.5g/kg(0.25%) 첨가시 일당증체량에서 3%, 일당사료섭취량에서 4.2%의 증가를 보였으며, 5g/kg 첨가시 각각 6.6%, 7.2%의 향상효과를 보인 반면, ALA-키토산 발효물 합제의 경우 0.1% 첨가시 일당증체량과 사료효율에서 6.7%, 6.8%의 향상과 0.2% 첨가시 11.3%, 13.1% 향상 효과를 보였다.In the treatment of existing chitosan fermented products, the addition of 2.5g / kg (0.25%) increased the daily gain by 3% and the daily feed intake by 4.2%, and the addition of 5g / kg increased 6.6% and 7.2%, respectively. On the other hand, the ALA-chitosan fermented product mixture showed a 6.7% and 6.8% improvement in daily gain and feed efficiency with 0.1% addition and 11.3% and 13.1% improvement with 0.2% addition.
표 6. 성장 능력에 미치는 영향Table 6. Impact on growth capacity
<실시예 5. ALA-키토산 발효물 합제의 일반성분 소화율><Example 5. General ingredient digestibility of ALA-chitosan fermented product mixture>
이유자돈 사료 내 ALA-키토산 발효물 합제의 첨가가 일반성분 소화율에 미치는 영향은 표 7에 나타내었다. 1주차 건물 소화율(DM)에서 ANT, AF2 처리구가 가장 높은 소화율을 보였으며(P<0.05), AF1 처리구가 대조구보다 유의적으로 높았다(P<0.05). 질소 소화율(N)에서는 대조구가 가장 낮은 결과를 보였으며(P<0.05), AF1 처리구가 ANT 처리구보다 유의적으로 낮았다(P<0.05). 3주차 건물 소화율에서는 대조구가 다른 처리구들보다 유의적으로 낮았고(P<0.05), 질소 소화율에 있어서 ANT와 AF2 처리구가 대조구보다 유의적으로 높았다(P<0.05). 종료시 건물 소화율에서는 ANT, AF2 처리구가 대조구보다 높았고(P<0.05), 질소 소화율에서는 대조구가 가장 낮은 결과를 보였다(P<0.05).The effect of the addition of ALA-chitosan fermented product mixture on weaning piglet diets is shown in Table 7. At week 1, the ANT and AF2 treatments showed the highest digestibility (P <0.05), and the AF1 treatments were significantly higher than the control (P <0.05). In the nitrogen digestibility (N), the control showed the lowest results (P <0.05), and the AF1 treatment was significantly lower than the ANT treatment (P <0.05). At 3 weeks of building digestibility, the control was significantly lower than the other treatments (P <0.05), and the ANT and AF2 treatments were significantly higher than the control (P <0.05). At the end of the treatment, ANT and AF2 treatments were higher than control (P <0.05), and nitrogen control rate was the lowest (P <0.05).
기존 ALA 처리시 시험 전체 기간종안 5mg/kg 첨가시 건물과 질소 소화율에서 1.3%, 0.6% 향상, 10mg/kg 첨가시 2.3%, 1.4% 향상, 15mg/kg 첨가시 6.5%, 5.6% 향상을 보였다. 또한 키토산 발효물 처리시 2.5g/kg(0.25%) 첨가시 3.5%, 3.7%의 향상과 5g/kg(0.5%) 첨가시 6.6%, 8.6%의 향상을 보였다. In addition, 5 mg / kg of total ALA treatment resulted in 1.3% and 0.6% improvement in dry matter and nitrogen digestibility, 2.3% and 1.4% in 10mg / kg, and 6.5% and 5.6% in 15mg / kg. . In addition, the addition of 2.5g / kg (0.25%) improved 3.5% and 3.7% for chitosan fermentation, and 6.6% and 8.6% for 5g / kg (0.5%).
ALA-키토산 발효물 합제의 경우 시험개시 1주차에 0.1% 첨가시 건물과 질소 소화율에서 14.5%, 23.3%의 증가효과를 보였으며, 0.2% 첨가시 18.0%, 28.2%의 소화율 향상을 보였다.In the case of ALA-chitosan fermentation mixture, 0.1% addition of 1% at the beginning of the test showed 14.5% and 23.3% increase in dry matter and nitrogen digestibility, and 0.2% addition showed 18.0% and 28.2% improvement in digestibility.
표 7. 건물과 질소 소화율에 미치는 영향Table 7. Effect on building and nitrogen digestibility
<실시예 4. ALA-키토산 발효물 합제의 첨가가 혈액내 면역지표에 미치는 영향>Example 4 Effect of ALA-chitosan Fermentation Combination on Blood Immune Indicators
이유자돈 사료 내 ALA-키토산 발효물 합제의 첨가가 혈액내 면역지표에 미치는 영향은 표 8에 나타내었다. RBC, WBC, Hb, Iron, TIBC에서는 각 처리구간에 차이를 보이지 않았다(P>0.05). 그러나 시험종료시 Lymphocyte 함량에 있어서는 대조 구가 ALA-키토산 발효물 합제를 첨가한 AF1 및 AF2 처리구보다 유의적으로 높은 결과를 보였다(P<0.05).The effect of the addition of ALA-chitosan fermented product mixture in weaned pig diet on the immunomarker in blood is shown in Table 8. RBC, WBC, Hb, Iron, and TIBC showed no difference among treatments (P> 0.05). However, the control group showed significantly higher results in lymphocyte content than the AF1 and AF2 treatments with ALA-chitosan fermentation mixture (P <0.05).
ALA-키토산 발효물 합제의 경우 시험종료시 0.1% 첨가시 림프구가 대조구 대비 72.3% 수준으로 보였으며, 0.2% 첨가시 76.6% 수준을 보임으로써 ALA 키토산 발효물 합제를 첨가함으로써 면역력 증진의 효과를 확인할 수 있었다.In the case of ALA-chitosan fermentation mixture, lymphocytes showed 72.3% level when 0.1% was added at the end of the test, and 76.6% level when 0.2% was added, and the effect of boosting immunity could be confirmed by adding ALA chitosan fermentation mixture. there was.
표 8. 혈액내 면역지표에 미치는 영향Table 8. Effect on Blood Immune Indicators
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080099261A KR101123944B1 (en) | 2008-10-09 | 2008-10-09 | Stock feed composition containing blend of 5-aminolevulinic acid and fermented kitosan as active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080099261A KR101123944B1 (en) | 2008-10-09 | 2008-10-09 | Stock feed composition containing blend of 5-aminolevulinic acid and fermented kitosan as active ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100040165A true KR20100040165A (en) | 2010-04-19 |
KR101123944B1 KR101123944B1 (en) | 2012-03-23 |
Family
ID=42216356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080099261A KR101123944B1 (en) | 2008-10-09 | 2008-10-09 | Stock feed composition containing blend of 5-aminolevulinic acid and fermented kitosan as active ingredient |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101123944B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101314806B1 (en) * | 2011-06-10 | 2013-10-08 | 제너럴바이오(주) | Animal feed containing powder and extracts of 5-Aminolevulinic acid, Sanguisorba officinalis L. and Rhus japonica L. |
CN112075551A (en) * | 2020-09-28 | 2020-12-15 | 北京挑战农业科技有限公司 | Additive for improving survival rate of aquaculture animals and application thereof |
CN117243293B (en) * | 2023-11-13 | 2024-01-30 | 北京挑战生物技术有限公司 | Application of 5-aminolevulinic acid in preparation of product for preventing and treating constipation of sow |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4621043A (en) * | 1983-01-31 | 1986-11-04 | E. I. Du Pont De Nemours And Company | Storage stable photopolymerizable composition |
KR100262110B1 (en) * | 1998-01-20 | 2000-08-01 | 조건식 | Feed-additive by chitosan and mixed-feed preparation method by using it. |
KR100459918B1 (en) * | 2002-06-19 | 2004-12-03 | (주)엔바이로젠 | A livestock feed additive comprising δ-aminolevulinic acid for enhancing viability of livestock |
KR101283410B1 (en) * | 2006-05-29 | 2013-07-08 | 주식회사 씨티씨바이오 | Method for improving a drug or feed intake rate of shrimp |
-
2008
- 2008-10-09 KR KR1020080099261A patent/KR101123944B1/en not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101314806B1 (en) * | 2011-06-10 | 2013-10-08 | 제너럴바이오(주) | Animal feed containing powder and extracts of 5-Aminolevulinic acid, Sanguisorba officinalis L. and Rhus japonica L. |
CN112075551A (en) * | 2020-09-28 | 2020-12-15 | 北京挑战农业科技有限公司 | Additive for improving survival rate of aquaculture animals and application thereof |
CN117243293B (en) * | 2023-11-13 | 2024-01-30 | 北京挑战生物技术有限公司 | Application of 5-aminolevulinic acid in preparation of product for preventing and treating constipation of sow |
Also Published As
Publication number | Publication date |
---|---|
KR101123944B1 (en) | 2012-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kamal et al. | Effect of dietary supplementation of organic acids on performance and serum biochemistry of broiler chicken | |
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) | Scientific Opinion on the potential reduction of the currently authorised maximum zinc content in complete feed | |
RU2711259C1 (en) | Method for preparation of fodder additive for young cattle | |
JP2002544213A (en) | Composition comprising carvacrol and thymol for use as a fungicide | |
JP2024074847A (en) | Feed additive composition and feed composition containing same | |
KR101123944B1 (en) | Stock feed composition containing blend of 5-aminolevulinic acid and fermented kitosan as active ingredient | |
RU2285399C1 (en) | Method for increasing meat productivity of youngsters in fattening swine | |
CN111903863A (en) | Compound feed additive for improving bone and joint health of pets and application thereof | |
EP2713767A1 (en) | Use of 25-hydroxy vitamin d3 to promote phosphorous utilisation in ruminants | |
KR20090027269A (en) | Feed composition replacing antibiotics using delta-aminolevulinic acid | |
KR20200102648A (en) | 5-Adding livestock feed containing the efficacy of a mixture of aminorevulcanic acid (ALA) and kittoic acid ferments | |
RU2514642C1 (en) | Premix for farm birds | |
RU2714262C1 (en) | Method of using activated coal fodder additive | |
EP4378320A1 (en) | Use of furan formic acid compound in preparing animal feed additive | |
CN105767546B (en) | A kind of piglet premixed feed and mixed feed | |
Rezai et al. | Effect of rumen undegradable protein (RUP) on colostrum quality and growth of lori Bakhtiari lambs | |
WO1999032144A1 (en) | Method for preventing/remedying mastitis | |
RU2603266C1 (en) | Method of productive qualities and safety increase during nursery period | |
JPH0233348B2 (en) | ||
CN108967703A (en) | A kind of green feed additive, premix and mixed feed improving blue pool Meat | |
KR102371548B1 (en) | Food Composition for Spayed Companion Animal | |
KR20020090267A (en) | pig feed compound for substituting antibiotic medicine and producing method thereof | |
KR100877800B1 (en) | Feed Composition for Livestock | |
RU2669301C1 (en) | Method of manufacture of feed mixture for efficiently fattening of cast ewe | |
Coble et al. | 299 Effect of diet type and added copper on growth performance, carcass characteristics, total tract digestibility, gut morphology, and mucosal mRNA expression of finishing pigs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20150120 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20161227 Year of fee payment: 6 |
|
LAPS | Lapse due to unpaid annual fee |